Calimmune Inc. and HTG Molecular Diagnostics Inc. of Tucson will be joined by Phoenix-based VisionGate Inc. and recognized at the AZBio Awards on Oct. 1 at the Phoenix Convention Center. HTG Molecular has commercialized its HTG Edge instrument platform and a portfolio of gene-based tests using its proprietary, RNA-based technology.
In recognition of its contribution to new innovations and tools in the field of molecular diagnostics for the advancement of precision medicine, HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has been named a 2015 AZBio Fast Lane Company by the Arizona Bioindustry Association (AZBio).
Please join HTG Molecular’s presentation at the 2015 Personalized Medicine World Conference January 26 at 1:15 pm,Track 1 to learn more about HTG’s NGS-based sequencing molecular profiling. Or meet with us at the conference January 26 - 28.
NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has entered the next-generation sequencing space with the launch of its first assay, which targets and sequences 2,275 microRNAs using its proprietary nuclease protection probe technology.
HTG Molecular announced a deal with Ovagene Oncology this week that will see Ovagene adopt HTG’s Edge System for its menu of gynecological cancer-focused tests.
HTG Molecular is preparing a triad of submissions for its Edge System in the US, EU, and Canada, a company executive said this week.
TUCSON, Ariz.—HTG Molecular Diagnostics and the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) have finalized a license agreement that provides HTG exclusive rights to commercialize PROOF Centre-developed gene expression blood tests to evaluate the prognosis of chronic obstructive pulmonary disease (COPD) patients who are likely to experience frequent exacerbations known as lung attacks.
After a major nuclear accident, identifying early on which victims were zapped with the most radiation could help save lives.
TUCSON, Ariz.—HTG Molecular Diagnostics is collaborating with the John Wayne Cancer Institute (JWCI) to market its melanoma signature assays.
A biomarker discovery collaboration between HTG Molecular Diagnostics and Sanofi US will use HTG’s quantitative nucleic acid protection, or qNPA, technology to identify molecular targets in white blood cells associated with response to an unnamed cancer drug.
Cowboy boots and rodeos. White coats and laboratories. They’re both a great match for Tucson.
ADVANCE talks with TJ Johnson, CEO of HTG Molecular Diagnostics, about the future of the clinical laboratory.
Page last updated March 20, 2023